PT2929891T - Método para modulação do apetite - Google Patents

Método para modulação do apetite

Info

Publication number
PT2929891T
PT2929891T PT151637485T PT15163748T PT2929891T PT 2929891 T PT2929891 T PT 2929891T PT 151637485 T PT151637485 T PT 151637485T PT 15163748 T PT15163748 T PT 15163748T PT 2929891 T PT2929891 T PT 2929891T
Authority
PT
Portugal
Prior art keywords
modulating appetite
appetite
modulating
Prior art date
Application number
PT151637485T
Other languages
English (en)
Original Assignee
St Vincents Hospital Sydney Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2929891(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2004901957A external-priority patent/AU2004901957A0/en
Application filed by St Vincents Hospital Sydney Ltd filed Critical St Vincents Hospital Sydney Ltd
Publication of PT2929891T publication Critical patent/PT2929891T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/303—Eating disorders, e.g. anorexia, bulimia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT151637485T 2004-04-13 2005-04-13 Método para modulação do apetite PT2929891T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2004901957A AU2004901957A0 (en) 2004-04-13 Method for modulating appetite

Publications (1)

Publication Number Publication Date
PT2929891T true PT2929891T (pt) 2020-04-08

Family

ID=35149777

Family Applications (2)

Application Number Title Priority Date Filing Date
PT151637485T PT2929891T (pt) 2004-04-13 2005-04-13 Método para modulação do apetite
PT111838843T PT2441466E (pt) 2004-04-13 2005-04-13 Agente de inibição de mic-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT111838843T PT2441466E (pt) 2004-04-13 2005-04-13 Agente de inibição de mic-1

Country Status (12)

Country Link
US (6) US8192735B2 (pt)
EP (4) EP2929891B1 (pt)
JP (4) JP5448338B2 (pt)
CA (2) CA2561877C (pt)
CY (1) CY1115731T1 (pt)
DK (2) DK2441466T3 (pt)
ES (3) ES2788868T3 (pt)
HK (2) HK1215932A1 (pt)
PL (2) PL2441466T3 (pt)
PT (2) PT2929891T (pt)
SI (1) SI2441466T1 (pt)
WO (1) WO2005099746A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2441466T3 (pl) * 2004-04-13 2015-01-30 St Vincents Hospital Sydney Ltd Środek hamujący MIC-1
KR101245877B1 (ko) * 2006-08-04 2013-03-20 메디치니쉐 호흐슐레 하노버 Ｇｄｆ-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법
EP2783698A1 (en) 2007-08-16 2014-10-01 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
AU2008310310A1 (en) * 2007-10-09 2009-04-16 St Vincent's Hospital Sydney Limited A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
US20120107420A1 (en) 2008-10-31 2012-05-03 St Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
MX343729B (es) * 2011-04-08 2016-11-18 Amgen Inc Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos.
EP3683228A3 (en) 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
WO2013148117A1 (en) * 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
KR101838786B1 (ko) 2012-09-26 2018-03-15 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 성장 및 분화 인자 15 (gdf-15)에 대한 모노클로날 항체
KR102208861B1 (ko) 2012-12-21 2021-01-27 아베오 파마슈티컬즈, 인크. 항-gdf15 항체
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
MA38873B1 (fr) 2013-07-31 2018-11-30 Amgen Inc Constructions contenant le facteur 15 de différentiation de croissance (gdf-15)
GB2524553C (en) * 2014-03-26 2017-07-19 Julius-Maximilians-Universitãt Würzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB2524552B (en) * 2014-03-26 2017-07-12 Julius-Maximilians-Universitãt Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
PL3122775T3 (pl) * 2014-03-26 2020-05-18 Julius-Maximilians-Universität Würzburg Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworu
WO2015196145A1 (en) * 2014-06-20 2015-12-23 Aveo Pharmaceuticals, Inc. Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
WO2015196142A1 (en) * 2014-06-20 2015-12-23 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3157942B1 (en) * 2014-06-23 2020-06-17 Novartis AG Site specific protein modifications
RU2017101436A (ru) 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
AP2016009663A0 (en) 2014-07-30 2016-12-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
US20170306008A1 (en) * 2014-09-25 2017-10-26 Aveo Pharmaceuticals, Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
JP2018502908A (ja) * 2014-12-22 2018-02-01 ノヴォ ノルディスク アー／エス アルファ‐１‐ アンチトリプシン（ａ１ａｔ）融合タンパク質及びその使用
AU2016333538B2 (en) 2015-10-02 2022-03-31 Julius-Maximilians-Universität Würzburg GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
EA201890850A1 (ru) * 2015-10-02 2018-09-28 Юлиус-Максимилианс-Универзитет Вюрцбург Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
EP3425392A4 (en) 2016-02-29 2020-02-05 Public University Corporation Yokohama City University METHOD FOR DETECTING CASTRATION-RESISTANT PROSTATE CANCER AND REAGENT REAGENT
JP7021099B2 (ja) 2016-03-31 2022-02-18 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 結合タンパク質及びその使用方法
US11312766B2 (en) 2016-04-27 2022-04-26 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
CA3025251A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and uses thereof
JP2020503842A (ja) * 2016-10-12 2020-02-06 ヤンセン バイオテツク，インコーポレーテツド Ｇｄｆ１５様生物活性の調節因子をスクリーニングするための方法
EP3551214B1 (en) * 2016-12-06 2024-03-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019004550A1 (ko) * 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
JP7127422B2 (ja) 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
CN111163795A (zh) 2017-09-10 2020-05-15 诺沃挪第克公司 用于治疗肥胖症的mic-1和glp-1
CA3096097A1 (en) 2018-04-09 2019-10-17 Amgen Inc. Growth differentiation factor 15 fusion proteins
CN112912395A (zh) 2018-08-20 2021-06-04 辉瑞公司 抗gdf15抗体、组合物和使用方法
US10706329B2 (en) * 2018-11-13 2020-07-07 CurieAI, Inc. Methods for explainability of deep-learning models
JP2023503472A (ja) 2019-11-26 2023-01-30 ユーハン・コーポレイション 長時間作用型ｇｄｆ１５融合タンパク質およびそれを含む医薬組成物
KR20230165285A (ko) 2021-03-31 2023-12-05 캠브리지 엔터프라이즈 리미티드 Gdf15 신호전달의 치료적 억제제
JP2024519950A (ja) 2021-05-21 2024-05-21 ユハン コーポレーション Ｇｄｆ１５変異体及びｇｌｐ－１受容体作動薬を含む併用投与用組成物
JP2024519951A (ja) 2021-05-21 2024-05-21 ユハン コーポレーション ＧＤＦ１５変異体を含む非アルコール性脂肪性肝疾患または非アルコール性脂肪性肝炎の予防または治療用組成物｛Ｃｏｍｐｏｓｉｔｉｏｎ Ｆｏｒ Ｐｒｅｖｅｎｔｉｎｇ ｏｒ Ｔｒｅａｔｉｎｇ Ｎｏｎ－Ａｌｃｏｈｏｌｉｃ Ｆａｔｔｙ Ｌｉｖｅｒ Ｄｉｓｅａｓｅ ｏｒ Ｎｏｎ－Ａｌｃｏｈｏｌｉｃ Ｓｔｅａｔｏｈｅｐａｔｉｔｉｓ Ｃｏｍｐｒｉｓｉｎｇ Ｇｒｏｗｔｈ Ｄｉｆｆｅｒｅｎｔｉａｔｉｏｎ Ｆａｃｔｏｒ－１５ Ｖａｒｉａｎｔ｝
WO2023018803A1 (en) 2021-08-10 2023-02-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0833912B1 (en) 1995-06-22 2009-02-25 St Vincent's Hospital Sydney Limited Novel tgf-beta like cytokine
WO1999006445A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
AU1103900A (en) 1998-10-07 2000-04-26 Stryker Corporation Modified tgf-beta superfamily proteins
ATE384265T1 (de) * 2000-04-20 2008-02-15 St Vincents Hosp Sydney Diagnostischer assay mit dem makrophagen- inhibitorischen-zytokin-1 (mic-1)
WO2002020759A2 (en) * 2000-09-08 2002-03-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
US7157235B2 (en) * 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
PL2441466T3 (pl) * 2004-04-13 2015-01-30 St Vincents Hospital Sydney Ltd Środek hamujący MIC-1
JP5372380B2 (ja) * 2005-01-24 2013-12-18 ペプスキャン システムズ ベー．フェー． 結合化合物、免疫原性化合物およびペプチド模倣体
US20100204123A1 (en) 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease

Also Published As

Publication number Publication date
EP2929891A1 (en) 2015-10-14
PL2441466T3 (pl) 2015-01-30
EP1734986A1 (en) 2006-12-27
EP2774620A1 (en) 2014-09-10
JP5806275B2 (ja) 2015-11-10
CA2561877C (en) 2017-03-14
JP2013209376A (ja) 2013-10-10
DK2929891T3 (da) 2020-05-11
US20110123454A1 (en) 2011-05-26
PT2441466E (pt) 2014-09-09
US8946146B2 (en) 2015-02-03
EP1734986A4 (en) 2009-07-22
DK2441466T3 (da) 2014-10-27
JP5767667B2 (ja) 2015-08-19
HK1168274A1 (en) 2012-12-28
JP2014051511A (ja) 2014-03-20
ES2555956T3 (es) 2016-01-11
US20180346560A1 (en) 2018-12-06
US20160289320A1 (en) 2016-10-06
JP2007532586A (ja) 2007-11-15
CY1115731T1 (el) 2017-01-25
CA2561877A1 (en) 2005-10-27
US20210340243A1 (en) 2021-11-04
WO2005099746A1 (en) 2005-10-27
EP1734986B1 (en) 2015-11-11
EP2441466B1 (en) 2014-07-23
EP2441466A1 (en) 2012-04-18
CA2905125C (en) 2017-02-07
ES2788868T3 (es) 2020-10-23
JP2011190262A (ja) 2011-09-29
EP2929891B1 (en) 2020-03-11
US8192735B2 (en) 2012-06-05
US20150183861A1 (en) 2015-07-02
CA2905125A1 (en) 2005-10-27
JP5448338B2 (ja) 2014-03-19
SI2441466T1 (sl) 2015-01-30
US20090004181A1 (en) 2009-01-01
PL2929891T3 (pl) 2020-08-24
HK1215932A1 (zh) 2016-09-30
ES2518865T3 (es) 2014-11-05

Similar Documents

Publication Publication Date Title
HK1215932A1 (zh) 調節食慾的方法
ZA200704202B (en) Method for preparing n-phenylpyrazole-1-carboxamides
GB0420061D0 (en) Method
GB0402639D0 (en) Method
GB0422733D0 (en) Method
GB0410478D0 (en) Method
GB0422730D0 (en) Method
GB0419419D0 (en) Method
GB0418651D0 (en) Method
GB0415009D0 (en) Method
GB0412672D0 (en) Method
GB0412659D0 (en) Method
GB0420815D0 (en) Method
GB0414787D0 (en) Method
GB0405751D0 (en) Method
GB0419405D0 (en) Method
TWI315261B (en) Method for transferring-printing
AU2004901957A0 (en) Method for modulating appetite
GB0415081D0 (en) Method
GB0413714D0 (en) Method
ZA200500148B (en) Method for nano-sizing
GB0402123D0 (en) Method
GB0406989D0 (en) Method
GB0412671D0 (en) Method
GB0404931D0 (en) Method